Skip to Content
Webinar Recording

Nivolumab & Hyaluronidase for Subcutaneous Administration: A Review of Efficacy and Safety Results from CheckMate 67TOPTA Monthly Meeting – April 2025

Recorded on: April 10, 2025

 

 

Exploring a New Approach to Nivolumab Delivery

Join us for an in-depth review of Nivolumab and Hyaluronidase for Subcutaneous Administration—also known as OPDIVO Qvantig—an FDA-approved subcutaneous injection that offers a 3–5 minute alternative to traditional infusion.

Presented by Rehan Uddin, PharmD of Bristol Myers Squibb, this session will provide an overview of:

  • The role of OPDIVO Qvantig as a subcutaneous formulation of Nivolumab

  • Dosing and administration guidance

  • Efficacy and safety data

  • Key findings from the CheckMate 67T clinical trial

 

If you have any questions or would like to request the meeting invite, contact Jonathan Rivera.